{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-012415","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.297061+00:00","generated_at":"2026-06-16T21:18:42.622062+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Avalo Therapeutics terminates $50M at-the-market equity offering with Cantor and RBC","bullets":["On April 20, 2023, Avalo delivered notice to Cantor and RBC to terminate the Sales Agreement, effective by April 30, 2023.","The agreement allowed sale of up to $50M of common stock through the sales agents.","No termination penalties are associated with the termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-012415","json":"https://secwatch.observer/filing/0001628280-23-012415.json","markdown":"https://secwatch.observer/filing/0001628280-23-012415.md","text":"https://secwatch.observer/filing/0001628280-23-012415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023012415/0001628280-23-012415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023012415/avtx-20230420.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T21:18:42.622062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5c2a699f1a694e94daf186ae15e73974a334f89","claim":"Avalo Therapeutics, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC valued at Termination of Controlled Equity Offering Sales Agreement (up to $50.0 million aggregate offering pr (effective 2023-04-30).","evidence_excerpt":"Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed in July 2021, Avalo Therapeutics, Inc. (the “Company”), entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and RBC Capital Markets, LLC (“RBC”, and collectively with Cantor, the “Sales Agents”), as sales agents, pursuant to which the Company may offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million. On April 20, 2023, the Company delivered written notice to Cantor and RBC to terminate the Sales Agreement, effective no later than April 30, 2023, pursuant to Section 12(b) of the Sales Agreement. The Company is not subject to any termination penalties related to the termination of the Sales Agreement. The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by referen","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023012415/0001628280-23-012415-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co. and RBC Capital Markets, LLC"},{"label":"Value","value":"Termination of Controlled Equity Offering Sales Agreement (up to $50.0 million aggregate offering pr"},{"label":"Effective","value":"2023-04-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}